Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in ...
Doctors address the pros and cons of Health Resources and Services Administration’s new guidance, including at-home ...
Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment ...
TUCSON, Ariz., June 16, 2015 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL ...
The Food and Drug Administration approved the expanded use of the biomarker test CINtec PLUS Cytology that looks at HPV related biomarkers that could lead to cervical cancer. This is the first triage ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm has received clearance from the ...
DUBLIN--(BUSINESS WIRE)--The "Global Cytology Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The cytology market will register a CAGR of nearly 7% by 2022. The screening ...
Researchers determined that women ≥55 years of age who underwent a single HPV DNA test with a negative diagnosis as well as routine cytology were found to be at low risk for cervical cancer. For women ...
IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging, and immunohistochemical study in 34 patients with glioma. Background: Cerebrospinal ...
We included 717 cancers from 23 studies. The pooled sensitivity of cytology to cancer at a cutoff of a high-grade squamous intraepithelial lesion (HSIL) or worse was 79.4% (95% CI, 67.7% to 86.0%).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results